<p>EktaH has advanced its lead oral obesity candidate, NKS-3, into Phase II clinical development and has enrolled the first patient in the exploratory Phase IIa SERENITY-1 study in Tunisia. The post EktaH advances NKS-3 into Phase II obesity development appeared first on Longevity.Technology.</p>